NASDAQ:LBPS

4D pharma Stock Forecast, Price & News

$9.90
+0.20 (+2.06 %)
(As of 08/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.90
$9.92
50-Day Range
$9.00
$11.97
52-Week Range
$8.97
$15.50
Volume1,187 shs
Average Volume10,594 shs
Market Capitalization$162.66 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04
30 days | 90 days | 365 days | Advanced Chart
Receive LBPS News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.


About 4D pharma

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

524th out of 2,226 stocks

Pharmaceutical Preparations Industry

259th out of 870 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











4D pharma (NASDAQ:LBPS) Frequently Asked Questions

Is 4D pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 4D pharma stock.
View analyst ratings for 4D pharma
or view top-rated stocks.

What stocks does MarketBeat like better than 4D pharma?

Wall Street analysts have given 4D pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 4D pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for LBPS?

2 brokerages have issued 12 month price objectives for 4D pharma's shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate 4D pharma's stock price to reach $37.50 in the next year. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for 4D pharma
or view top-rated stocks among Wall Street analysts.

Who are 4D pharma's key executives?

4D pharma's management team includes the following people:
  • Mr. Duncan Joseph Peyton, CEO & Exec. Director (Age 51, Pay $141.03k)
  • Dr. Alexander James Stevenson, Chief Scientific Officer & Exec. Director (Age 49, Pay $141.03k)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 61)
  • Fay Weston, Head of Investor Relations
  • Mr. Adrian Murray, Gen. Counsel (Interim)
  • Mr. Glenn Dourado, Chief Bus. Officer
  • Mr. Richard Avison, Group Fin. Director

Who are some of 4D pharma's key competitors?

What is 4D pharma's stock symbol?

4D pharma trades on the NASDAQ under the ticker symbol "LBPS."

Who are 4D pharma's major shareholders?

4D pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.02%).

Which institutional investors are buying 4D pharma stock?

LBPS stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc..

How do I buy shares of 4D pharma?

Shares of LBPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 4D pharma's stock price today?

One share of LBPS stock can currently be purchased for approximately $9.90.

How much money does 4D pharma make?

4D pharma has a market capitalization of $162.66 million and generates $690,000.00 in revenue each year. The company earns $-30,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does 4D pharma have?

4D pharma employs 92 workers across the globe.

What is 4D pharma's official website?

The official website for 4D pharma is www.4dpharmaplc.com.

Where are 4D pharma's headquarters?

4D pharma is headquartered at 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ.

How can I contact 4D pharma?

4D pharma's mailing address is 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ. The company can be reached via phone at 44 11 3895 0130 or via email at [email protected]


This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.